TY - JOUR
T1 - RET signaling in prostate cancer
AU - Ban, Kechen
AU - Feng, Shu
AU - Shao, Longjiang
AU - Ittmann, Michael
N1 - Funding Information:
This work was supported by grants from the Department of Defense Prostate Cancer Research Program (W81XWH-14-1-0505; to M. Ittmann), the Prostate Cancer Foundation (to M. Ittmann), the Department of Veterans Affairs Merit Review program (5-IO1 BX002560-02; to M. Ittmann), the National Cancer Institute to the Dan L. Duncan Cancer (P30 CA125123) supporting the Human Tissue Acquisition and Pathology Shared Resource and by the use of the facilities of the Michael E. DeBakey VAMC.
Publisher Copyright:
©2017 AACR.
PY - 2017/8/15
Y1 - 2017/8/15
N2 - Purpose: Large diameter perineural prostate cancer is associated with poor outcomes. GDNF, with its coreceptor GFRa1, binds RET and activates downstream pro-oncogenic signaling. Because both GDNF and GFRa1 are secreted by nerves, we examined the role of RET signaling in prostate cancer. Experimental Design: Expression of RET, GDNF, and/or GFRa1 was assessed. The impact of RET signaling on proliferation, invasion and soft agar colony formation, perineural invasion, and growth in vivo was determined. Cellular signaling downstream of RET was examined by Western blotting. Results: RET is expressed in all prostate cancer cell lines. GFRa1 is only expressed in 22Rv1 cells, which is the only line that responds to exogenous GDNF. In contrast, all cell lines respond to GDNF plus GFRa1. Conditioned medium from dorsal root ganglia contains secreted GFRa1 and promotes transformation-related phenotypes, which can be blocked by anti-GFRa1 antibody. Perineural invasion in the dorsal root ganglion assay is inhibited by anti-GFRa antibody and RET knockdown. In vivo, knockdown of RET inhibits tumor growth. RET signaling activates ERK or AKT signaling depending on context, but phosphorylation of p70S6 kinase is markedly increased in all cases. Knockdown of p70S6 kinase markedly decreases RET induced transformed phenotypes. Finally, RET is expressed in 18% of adenocarcinomas and all three small-cell carcinomas examined. Conclusions: RET promotes transformation associated phenotypes, including perineural invasion in prostate cancer via activation of p70S6 kinase.
AB - Purpose: Large diameter perineural prostate cancer is associated with poor outcomes. GDNF, with its coreceptor GFRa1, binds RET and activates downstream pro-oncogenic signaling. Because both GDNF and GFRa1 are secreted by nerves, we examined the role of RET signaling in prostate cancer. Experimental Design: Expression of RET, GDNF, and/or GFRa1 was assessed. The impact of RET signaling on proliferation, invasion and soft agar colony formation, perineural invasion, and growth in vivo was determined. Cellular signaling downstream of RET was examined by Western blotting. Results: RET is expressed in all prostate cancer cell lines. GFRa1 is only expressed in 22Rv1 cells, which is the only line that responds to exogenous GDNF. In contrast, all cell lines respond to GDNF plus GFRa1. Conditioned medium from dorsal root ganglia contains secreted GFRa1 and promotes transformation-related phenotypes, which can be blocked by anti-GFRa1 antibody. Perineural invasion in the dorsal root ganglion assay is inhibited by anti-GFRa antibody and RET knockdown. In vivo, knockdown of RET inhibits tumor growth. RET signaling activates ERK or AKT signaling depending on context, but phosphorylation of p70S6 kinase is markedly increased in all cases. Knockdown of p70S6 kinase markedly decreases RET induced transformed phenotypes. Finally, RET is expressed in 18% of adenocarcinomas and all three small-cell carcinomas examined. Conclusions: RET promotes transformation associated phenotypes, including perineural invasion in prostate cancer via activation of p70S6 kinase.
UR - http://www.scopus.com/inward/record.url?scp=85028043793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028043793&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-17-0528
DO - 10.1158/1078-0432.CCR-17-0528
M3 - Article
C2 - 28490466
AN - SCOPUS:85028043793
SN - 1078-0432
VL - 23
SP - 4885
EP - 4896
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 16
ER -